William Westlin, Ph.D.
Chief Scientific Officer
William (Wes) Westlin, Ph.D., is the Chief Scientific Officer at eGenesis. Dr. Westlin bring his extensive biotech experiences to bear on fulfilling the promise of developing genetically engineered biocompatible organs to address the global organ transplant crisis through xenotransplantation. Prior to joining eGenesis, Dr. Westlin was Senior Vice President of Research and Early Development at both Nimbus Therapeutics and Avila Therapeutics where he led teams that advanced programs to early development using creative first-in-human study designs to generate clinical proof-of-concept. As part of the executive leadership teams, Dr. Westlin helped establish several critical partnerships with Sanofi, Celgene, Clovis Oncology, and Gilead Sciences. Before that, he served as the Senior Vice President for Preclinical Research at Praecis Pharmaceuticals, where he was responsible for preclinical research and early development in oncology, immunology, inflammation biology, and Alzheimer’s disease programs. Prior to joining Praecis, Dr. Westlin held scientific positions of increasing responsibility in the immunology, molecular pharmacology, and oncology research units of Monsanto/Searle and subsequently Pharmacia.
Dr. Westlin has authored more than 50 scientific publications in peer-reviewed journals and is a co-inventor on multiple patents. He received his Master’s and Ph.D. in Pharmacology from New York Medical College and held a post-doctoral fellowship with Harvard Medical School and Brigham and Women’s Hospital.